Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 148.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 103,865 shares of the company’s stock after purchasing an additional 62,016 shares during the quarter. SG Americas Securities LLC owned about 0.08% of Atossa Therapeutics worth $98,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ATOS. Intech Investment Management LLC purchased a new position in shares of Atossa Therapeutics in the 3rd quarter valued at $29,000. XTX Topco Ltd raised its stake in shares of Atossa Therapeutics by 101.2% in the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after acquiring an additional 24,951 shares during the period. The Manufacturers Life Insurance Company purchased a new position in shares of Atossa Therapeutics in the 3rd quarter valued at $75,000. JPMorgan Chase & Co. raised its stake in shares of Atossa Therapeutics by 177.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock valued at $227,000 after acquiring an additional 95,643 shares during the period. Finally, Barclays PLC raised its stake in shares of Atossa Therapeutics by 280.9% in the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after acquiring an additional 123,683 shares during the period. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Stock Performance

NASDAQ ATOS opened at $0.77 on Thursday. Atossa Therapeutics, Inc. has a one year low of $0.72 and a one year high of $2.31. The company has a 50-day simple moving average of $0.96 and a 200-day simple moving average of $1.23. The firm has a market capitalization of $96.69 million, a PE ratio of -3.49 and a beta of 1.24.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research note on Thursday, January 30th. Ascendiant Capital Markets lifted their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.